Total Insider Purchases and Sales Reported to the SEC. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. For the best MarketWatch.com experience, please update to a modern browser. Company profile for Incyte Corp. including key executives, insider trading, ownership, revenue and average growth rates. View detailed INCY description & address. In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million. Lists ranking Incyte. Incyte Ltd has been running for 13 years. Something went wrong while loading Watchlist. * INCYTE ANNOUNCES PIVOTAL REACH2 STUDY DATA PUBLISHED IN NEJM HIGHLIGHT SUPERIOR EFFICACY OF RUXOLITINIB (JAKAFI®) VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE Source text for Eikon: Further company coverage: * FDA APPROVES FIRST TARGETED TREATMENT FOR PATIENTS WITH CHOLANGIOCARCINOMA, A CANCER OF BILE DUCTS, * INCYTE ANNOUNCES INITIATION OF PHASE 3 RUXCOVID STUDY EVALUATING RUXOLITINIB (JAKAFI®) AS A TREATMENT FOR PATIENTS WITH COVID-19 ASSOCIATED CYTOKINE STORM, * FIRST PRESENTATION OF PHASE 3 DATA FROM TRUE-AD PROGRAM OF RUXOLITINIB CREAM AT REVOLUTIONIZING ATOPIC DERMATITIS VIRTUAL SYMPOSIUM. Japan. NOTIFIED CO THAT SHOULD HE BE RE-ELECTED AS MEMBER OF BOARD HE WILL SERVE UNTIL 2021 ANNUAL MEETING, * INCYTE REPORTS 2020 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES UPDATES ON KEY CLINICAL PROGRAMS. Privacy Notice, and Go to the homepage. Site: incyte.com. Incyte Ltd is an active company incorporated on 16 August 2007 with the registered office located in Weston-super-Mare, Somerset. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors. ... INCY Profile. Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive … The firm's lead drug, Jakafi, treats two types . Profile data is unavailable for this security. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. All quotes are in local exchange time. Doing business as: INCYTE CORPORATION Incy Corporation. Incyte is a drug discovery and development company which hopes to build a proprietary product pipeline of novel small molecule drugs. (Annual sales and employees) What industry is the company in? Incyte, Corp is an American pharmaceutical company based in Alapocas, Delaware. Profile Incyte . Incyte might finally be convincing Wall Street that its pipeline is the real deal. Visit a quote page and your recently viewed tickers will be displayed here. Information on valuation, funding, cap tables, investors, and executives for inCyte Innovations. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). * INCYTE AND MORPHOSYS ANNOUNCE THE VALIDATION OF THE EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR TAFASITAMAB, * INCYTE - ON MAY 13 PAUL A. FRIEDMAN, M.D. The Company develops Jakafi (ruxolitinib), a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera when there has been an inadequate response to or … About the company Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. Unlock more with a D&B Hoovers FREE Trial. Description Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. Sweden. Historical and current end-of-day data provided by FACTSET. Registration: Nov 4, 2011. News. Description: Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. Incyte's product pipeline is currently focused on oncology and inflammation and includes compounds in various stages of development. Previous: 952Next: 954. The Netherlands. Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Company Profile. North America. Profile MORE. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte Biosciences UK Ltd. Incyte is a global biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. RANK 953. Incyte must face Novartis contract claims in blood drug royalty fight, BRIEF-Incyte And MorphoSys Announce The Validation Of The European Marketing Authorization Application For Tafasitamab, BRIEF-Incyte Says Paul Friedman Notified He Will Serve Until 2021 Annual Meeting If Re-Elected As Board Member, BRIEF-Incyte Reports Q1 Loss Per Share Of $3.33, BRIEF-Incyte Announces Pivotal Reach2 Study Data Published In Nejm Highlight Superior Efficacy Of Ruxolitinib Versus Best Available Therapy In Patients With Acute Graft-Versus-Host Disease, BRIEF-FDA Approves First Targeted Treatment For Patients With Cholangiocarcinoma, BRIEF-Incyte Announces Initiation Of Phase 3 Ruxcovid Study Evaluating Ruxolitinib (Jakafi®) As A Treatment For Patients With Covid-19 Associated Cytokine Storm, BRIEF-Incyte Says Phase 3 Data From True-Ad Program Of Ruxolitinib Cream Support Planned Submission Of NDA To US FDA In 2020, RPT-Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19, Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19, BRIEF-Incyte Announces Plans To Initiate A Phase 3 Clinical Trial Of Ruxolitinib (Jakafi®) As A Treatment For Patients With Covid-19 Associated Cytokine Storm, BRIEF-Incyte Names New Member To Its Board Of Directors, BRIEF-Morphosys Resolves Capital Increase To Implement Purchase Of ADSs By Incyte, BRIEF-Morphosys, Incyte Announce Antitrust Clearance Of Global Collaboration And License Agreement For Tafasitamab, BRIEF-Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream In Patients With Atopic Dermatitis, BRIEF-Incyte Corp - QTRLY Non-GAAP Diluted EPS $0.65, BRIEF-Lilly And Incyte Announce Positive Top-Line Results From The North American Phase 3 Study Of Oral Selective JAK Inhibitor Baricitinib In Patients With Moderate- To Severe Atopic Dermatitis, UPDATE 1-Incyte's skin disease drug meets main goal in late-stage study, Incyte's skin disease drug meets main goal in late-stage study, Incyte unlawfully marketed cancer drug Jakafi says whistleblower lawsuit. Incyte Company Profile Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. Delaware drug company Incyte Corp must face a lawsuit by Novartis Pharma AG accusing it of breaching a contract by reducing royalties it paid on a drug used to treat blood disorders the two companies developed together. Intraday data delayed at least 15 minutes or per exchange requirements. There are currently no items in this Watchlist. Incyte Corporation is a biopharmaceutical company. Find company research, competitor information, contact details & financial data for Incyte Biosciences Austria GmbH of Wien, Wien. The relentless pursuit of scientific excellence remains at the core of our company today. Company Profile and Business Description for Incyte Incyte Corporation, incorporated on April 8, 1991, is a biopharmaceutical company. Key Developments ... Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. This is the Incyte company profile. As of on the NASDAQ ∙ Minimum 15 minute delay, Baricitinib Is First JAK-Inhibitor To Demonstrate Hair Regrowth In Phase 3 Alopecia Areata Trial, Morphosys And Incyte Announce Acceptance By Health Canada Of The New Drug Submission For Tafasitamab, Incyte And Morphosys Announce Acceptance By Health Canada Of The New Drug Submission For Tafasitamab. Company Profile and Business Description for Incyte Incyte Corporation, incorporated on April 8, 1991, is a biopharmaceutical company. View Incyte Ltd profile, shareholders, contacts, financials, industry and description. Incyte Consulting Ltd has been running for 13 years. 'This is not a race': Philadelphia-area biotech firms, research institutions work to combat Covid-19 Denmark. Lists ranking Incyte. View detailed INCY description & address. Wilmington, Delaware 19803 … Incyte focuses on the discovery and development of small-molecule drugs. Create a list of the investments you want to track. There are currently 3 active directors and 1 active secretary according to the latest confirmation statement submitted on … Switzerland. Through partnerships with Novartis, Eli Lilly, and Pfizer, Incyte intends to RANK 953. Company profile page for Incyte Corp including stock price, company news, press releases, executives, board members, and contact information Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into … Incyte Corporation Company Profile 1801 Augustine Cut-Off. Doing business as: INCYTE CORPORATION Incy Corporation. Incyte is committed to the rigorous pursuit of research and development excellence to improve the lives of patients, make a difference in health care, and build sustainable value. Incyte is committed to the rigorous pursuit of research and development excellence to improve the lives of patients, make a difference in health care, and build sustainable value. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making.